**SUPPLEMENTARY FIGURE 1.** Bland-Altman plot of subfoveal choroidal thickness measurements performed by two investigators independently of each other. The mean differences (a horizontal line between dotted lines) and the 95% confidence limits of the bias (dotted lines) are shown.

**SUPPLEMENTARY FIGURE 2.** Mean subfoveal choroidal thickness over time following anti-vascular endothelial growth factor (anti-VEGF) therapy in eyes with myopic choroidal
neovascularization (CNV). Overall, the thickness significantly decreases at 1 month after the anti-VEGF therapy ($P = 0.027$) whereas thickness at month 3 or 6 shows no significant difference with baseline thickness. The thickness at the final visit is also significantly smaller than that at baseline ($P = 0.006$)

**SUPPLEMENTARY FIGURE 3.** Mean choroidal thickness over time following anti-vascular endothelial growth factor (anti-VEGF) therapy in eyes with myopic choroidal neovascularization (CNV) at the 4 parafoveal locations (1 mm temporal, nasal, superior, and inferior to the fovea). The choroidal thickness at the locations decreases at the 1-month visit compared to the baseline. The difference is statistically significant in the temporal, superior, and inferior choroids.